Estrella Immunopharma, Inc. ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today ...

All figures are in United States dollars unless otherwise stated. This news release contains forward-looking information that ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

All figures are in United States dollars. All production figures reflect payable metal quantities and are on a 100% basis, unless otherwise ...